Research ArticleExperimental Studies

A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma

NADEZHDA ROMANCHIKOVA, ARNIS STRODS, JULIJA STRAZDINA, BORISS STRUMFS and PETERIS TRAPENCIERIS
Anticancer Research November 2016, 36 (11) 6133-6140;

Abstract

Background: Mantle cell lymphoma (MCL) is an aggressive non-Hodgkin's lymphoma characterized by hyperactive neoplastic B-cells and extended tumor cell survival. Bruton's tyrosine kinase (BTK), a crucial kinase in the B-cell antigen receptor signaling pathway, has emerged as a novel target of MCL therapy. A novel BTK-targeting inhibitor, JuSt-23F was prepared. Materials and Methods: The WST-8 assay was used to determine cytotoxicity and half-maximal inhibitory concentration (IC50) values for JuSt-23F against the MCL cell lines Mino and Maver-1. JuSt-23F-mediated apoptosis was assessed using the annexin V assay. We detected phosphorylation of p65/RelA on serine 536 in whole Jurkat, Mino and Maver-1 cells treated with JuSt-23F and stimulated with tumor necrosis factor (TNFα). We assessed JuSt-23F-mediated phosphorylation of the extracellular signal-regulated kinases 1 and 2 (ERK1/2) in T-cell lymphoma and MCL cells stimulated by phorbol-12-myristate-13-acetate (PMA). Results and Conclusion: Our study suggests that JuSt-23F inhibits apoptosis selectively in B-cell lymphoma cells. JuSt-23F exerts its antiproliferative effects on MCL cells through targeting the downstream BTK signaling cascade via down-regulation of nuclear factor kappa-light-chain-enhancer of activated B-cells and ERK1/2 pathways. Thus, our findings propose the novel BTK inhibitor JuSt-23F as an attractive potential agent for investigation and treatment of MCL.

Mantle cell lymphoma (MCL), a rare and aggressive form of B-cell non-Hodgkin's lymphoma, is usually diagnosed when it has already spread to the lymph nodes, bone marrow and other organs. Development of targeted cancer therapies, such as Bruton's tyrosine kinase (BTK) in the B-cell antigen receptor (BCR) pathway, allowed significant advances in the treatment of MCL. It was shown that inhibition of BTK induces apoptosis and reduces levels of the anti-apoptotic proteins, such as BCL2 and BCL-xL, which sensitize B-cell lymphoma to chemotherapy (1-4). Biochemical studies have shown that phospholipase C-γ2 plays an important role in B-cell signaling (5). Cell line experiments revealed that BCR cross-linking activates three distinct families of non receptor protein tyrosine kinases, SRC family kinases, SYK and BTK, and initiated downstream events. BCR cross-linking in B-cells activated distinct mitogen-activated protein kinases (MAPKs), extracellular signal-regulated kinase (ERK), c-Jun NH2-terminal kinase (JNK), p38 MAPK, nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), and as a result, affected regulation of apoptosis (6-9). Different kinases of BCR signaling, including SYK, LYN, and BTK, have been found to be phosphorylated in primary MCL, suggesting activation of this pathway (10). Further studies with the knockdown of BTK in MCL cells revealed significant inhibition of the NF-κB pathway, which is most important for MCL proliferation and cell migration (11-13). Rudelius and colleagues demonstrated constitutive activation of the PI3K/AKT signaling pathway in a subset of aggressive blastoid MCL variants. This signaling resulted in the activation of a number of well-known target genes and pathways, including the NF-κB pathway, enhancing survival and cell proliferation, and inhibiting apoptosis (14).

There is evidence suggesting that NF-κB is required for efficient transcription of the BTK gene (15). NF-κB is activated by a wide variety of stimuli, including inflammatory cytokines, such as tumor necrosis factor alpha (TNFα), and is critical for apoptotic responses in cancer progression (16, 17). NF-κB, which is a family of five transcriptional factors, including p50, p52, p65 (RelA), RelB and c-Rel, mediates their dimerization, nuclear localization and DNA binding (18). The association of the NF-κB p65/p50 dimer plays a pivotal role in regulating its nuclear translocation and gene transcription. Sakurai et al. demonstrated that TNFα induces the phosphorylation by IKK of p65 on serine 536 in vitro kinase assay and experiments in vivo (19). Furthermore, some groups investigating the regulatory mechanisms for p65 phosphorylation found that serine 536 phosphorylation was widely observed in accordance with the phosphorylation of IκBα (20-23).

Study of the pathogenesis of MCL revealed that the development of MCL was associated with the dysregulation of different signaling pathways involved in cell proliferation and survival, including those related to transcription factor NF-κB, AKT and ERK1/2 (24). Specific blockade of ERK1/2 pathway potentiates chemotherapy-induced apoptosis in lymphoma cells (25). It was shown that the compound 8-NH2-Ado, which was efficacious in preclinical models of MCL, dramatically reduced phosphorylation of kinases in the AKT and ERK1/2 pathways (26). Enhanced apoptosis in MCL cell lines and primary MCL cells was associated with JNK1/2 activation, and ERK1/2 and AKT1/2 inactivation (26, 27). Antitumor activity in animal models and, recently, significant clinical activity, was observed with small molecule inhibitors of protein kinases in the BCR pathway. High response rates were reported in patients with MCL (28, 29).

Since BTK has been shown to play an important role in a variety of cellular processes, including cell-cycle regulation and apoptosis, the BTK signaling pathway may represent an attractive approach for therapy of MCL. In this study, we investigated a novel small molecule BTK inhibitor JuSt-23F.

Materials and Methods

Synthesis of JuSt-23F and preparation of solutions. JuSt-23F was synthesized under the leadership of Dr. P. Trapencieris at the Latvian Institute of Organic Synthesis.

Stock solution was prepared by dissolving JuSt-23F in at 10 mM concentration. Depending on the experimental conditions, the stock solution of JuSt-23F was diluted with appropriate solvent.

Cell lines and cultivation. The following cell lines were obtained from the American Type Cell Culture Collection (ATCC): MCL cells Mino- (ATCC, CRL-3000) and Maver-1 (ATCC, CRL-3000); Jurkat, acute T-cell leukemia, T lymphocyte (ATCC, TIB-152). All cell lines were routinely maintained in RPMI-1640 medium supplemented with 2 mM L-glutamine and 10% fetal bovine serum, and were grown in culture in incubator at 37°C with 5% CO2 in a humidified atmosphere.

Assay of BTK activity in vitro. The luminescent kinase assay ADP-Glo™ (Promega, Madison, WI, USA) was used for the screening of BTK inhibitors. The assay detected the effects of novel chemical compounds on the catalytic activity of purified recombinant BTK. In the first step, ADP formed from a BTK reaction was converted into ATP which was further converted into light by Ultra-Glo™ Luciferase. The luminescent signal was measured and positively correlated with BTK activity. The assay was performed in white 96-well plate. Briefly, in the first step of the BTK kinase reaction: buffer (40 mM Tris pH 7.5, 20 mM MgCl2, and 0.1 mg/ml BSA) was mixed with 10 ng recombinant kinase, 1 μg peptide substrate Poly(Glu4Tyr1), 50 μM ATP, and the tested compound, or without it as control. After incubation for 30 min, an equal volume of ADP-Glo™ reagent was added to terminate the kinase reaction and deplete the remaining ATP. In the second step, the addition of double volume of the Kinase Detection reagent for 30 min resulted in simultaneous conversion of ADP to ATP. We then measured luminescence (RLU) on an Infinite M100 microplate reader (Tecan Group Ltd, Mannedorf, Switzerland) with integration time 750 ms.

Calculation percentage of BTK activity and IC50. The percentage of inhibition of BTK activity was calculated as: (RLUsample/RLUcontrol) ×100. The IC50 values were quantified using the percentage data and GraphPad Prism 5.03 software (GraphPad Software Inc., San Diego, CA, USA). All data are given as the mean of three independent experiments.

Apoptosis assay. Apoptosis detection was performed using the annexin V-FITC/propidium iodide fluorescent staining assay. Cells were plated at a density of 5×105 cells/ml in 100 μl per well of 96-well plates. Apoptosis was induced by treatingJurkat, Mino and Maver-1 cells with JuSt-23F at 12,5-100 μM. All samples were set up in triplicate. After 24 h of incubation, the cells were harvested, measured on a BD FACSAria II flow cytometer (BD Biosciences, San Jose, CA, USA) and analyzed with Flowing Software (Cell Imaging Core, Turku Centre for Biotechnology, Turku, Finland). Furthermore, the percentage of early plus late apoptotic untreated and JuSt-23F-treated cells was calculated. Percentage of apoptosis induction was calculated as the difference of apoptosis of JuSt-23F-treated cells and untreated cells for each JuSt-23Fconcentration.

WST-8 cell proliferation assay. To evaluate the effect of JuSt-23F on Jurkat, Mino and Maver-1 cell viability, we performed WST-8 assays (Cayman Chemical, Michigan, USA) according to the manufacturer's protocol. This proliferation assay was based on extracellular reduction of tetrazolium dye and formation of soluble formazan which positively correlates with cell viability (30). In brief, 5×104 cells/well were seeded in a 96-well plate in 100 μl of growth medium with JuSt-23F at 3.1-100 μM or without it as control. Each concentration of compound was used in triplicate wells with cells and one well as medium control. Plates were incubated in at 37°C with 5% CO2. After 24 h, 10 μl of WST-8 reagent was added to each well and incubation was continued for another 4 h. Soluble formazan was measured in cultivation medium at 450 nm using an Anthos HTII plate reader (Anthos Labtec instruments, Salzburg, Austria). The cytotoxicity and IC50 value were quantified using the absorbance data and GraphPad Prism 5.03 software (GraphPad Software Inc.). All data are given as the mean of three independent experiments

NF-κB phosphorylation assay. Cell-based ELISA (BioAssay Systems, Hayward, CA, USA) was used to measure the phosphorylation of p65/RelA on serine 536 (pNF-κB) in whole Jurkat, Mino and Maver-1 cells according to the manufacturer's protocol. For this assay, cells were plated at a density of 5×105 cells/ml into 96-well black plates and treated with different concentrations of JuSt-23F for 4 h and then induced by TNFα (5 ng/ml) for 15 min. Cells were then fixed and permeabilized in the wells. Phosphorylated and total NF-κB was measured using a double immunoenzymatic labeling procedure. pNF-κB fluorescence (FL) was read at Ex/Em of 535/585 nm and NF-κB at Ex/Em of 360/450 nm. The quantity of pNF-κB was normalized as: (ΔFLpNF-κB/ΔFLNF-κB)/(ΔFLpNF-κB/ΔFLNF-κB)0, where (ΔFLpNF-κB/ΔFLNF-κB)0 was the control reference value (untreated wells).

ERK1/2 phosphorylation assay. Cell-based ELISA (BioAssay Systems) measured dually phosphorylated ERK1/2 in mitogen-stimulated whole Jurkat, Mino and Maver-1 cells asdescribed elsewhere (31). In brief, cells were seeded at a density of 5×105 cells/ml in 96-well black plates in 100 μl, treated with JuSt-23F for 4 h and then induced by 50 nM phorbol-12-myristate-13-acetate (PMA) for 30 min. Cells were then fixed and permeabilized in the wells. Phosphorylated and total ERK was measured using a double immunoenzymatic labeling procedure. The fluorescence was read at Ex/Em of 535/590 nm for pERK and at Ex/Em of 360/450 nm for ERK detection. The quantity of pERK was normalized as: (ΔFLpERK/ΔFLERK)/(ΔFLpERK/ΔFLERK)0, where (ΔFLpERK/ΔFLERK)0 was the control reference value (untreated wells).

Statistical analysis. Student's t-test was used to analyze the difference between control and JuSt-23F-treated samples. Statistical significance was set at p<0.05. All data are given as the mean of three independent experiments.

Results

JuSt-23F inhibits BTK catalytic activity in vitro. Firstly, we inhibited BTK catalytic activity in vitro using luminescent kinase assay ADP-Glo™ and estimated IC50 values. Our experiments revealed that compound JuSt-23F, which belongs to the class of bis-2-arylaziridines, inhibited BTK enzymatic activity in a dose-dependent manner, with an IC50 value of 37.3 μM. Thus, our findings show that JuSt-23F is a potential BTK inhibitor.

JuSt-23F cytotoxicity towards MCL cells. A previous report demonstrated that the expression of BTK protein was detected in B-cells but not in T-cells (32). It was also shown that inhibition of BTK activity resulted in inhibition of cell proliferation and cell survival in various B-cell malignancies (32). We evaluated the cytotoxicity of JuSt-23F at concentrations ranging from 3.1 to 100 μM on MCL cell lines Mino and Maver-1 and T-cell lymphoma Jurkat. The IC50 values for Mino and Maver-1 cells were 32 μM and 37 μM, respectively, while that for Jurkat cells was 81 μM. Thus, we have shown that a 24 h treatment with JuSt-23F revealed a modest inhibitory effect on proliferation of MCL cells. JuSt-23F had no significant influence on T-cell survival. but shows antiproliferative effects against B-cell lymphoma cell lines Mino and Maver-1.

JuSt-23F selectively induces apoptosis of B-cell lymphoma cells. We further investigated whether JuSt-23F selectively inhibited B-cell growth by inducing cell death. We assayed for apoptosis in B-cell lymphoma cell lines Mino, Maver-1 and in Jurkat T-cells treated with JuSt-23F at 12.5-100 μM for 24 h. Analysis of apoptosis by flow cytometry demonstrated that T-cells did not significantly undergo apoptosis (Figure 1), being about 4% in both treated and untreated JuSt-23F cells. However, JuSt-23F treatment revealed extensive apoptosis of Mino and Maver-1 cells in a dose-dependent manner in comparison with untreated cells (Figure 1). JuSt-23F induced about 30% apoptosis of Mino cells and 40% of Maver-1 cells, but not of Jurkat cells (Figure 1B). JuSt-23F selectively induces apoptosis of B-cell lymphoma cells under our experimental conditions.

JuSt-23F down-regulates p65/RelA phosphorylation on serine 536 in MCL cells. NF-κB is a transcription factor that plays a central role in many physiological processes, e.g. inflammation, tumorigenesis and apoptosis. NF-κB is activated by a wide variety of stimuli, including inflammatory cytokines such as TNFα. A number of reports have demonstrated that NF-κB activation can maintain lymphoma cell viability (33-35). Inhibition of NF-κB resulted in lymphoma cells apoptosis in vitro and in clinical studies (11, 36). We assessed whether JuSt-23F mediates apoptosis through regulation of the NF-κB pathway. We found that JuSt-23F did not affect NF-κB phosphorylation in Jurkat cells (Figure 2A). However, we detected 1.4-fold inhibition of NF-κB phosphorylation in Mino cells and 2.8-fold inhibition in Maver-1 cells treated with 20 μM JuSt-23F (Figure 2B and C). TNFα-induced down-regulation of pNF-κB in Mino and Maver-1 cells was also determined in a dose-dependent manner (p<0.001; Figure 2B and C). We detected 1.9-fold inhibition of pNF-κB in Mino cells and 6.7-fold in Maver-1 cells induced with TNFα and treated with JuSt-23F (Figure 2B and C). Thus, we assume that JuSt-23F induction of apoptosis is regulated through down-regulation of p65/RelA phosphorylation of serine 536 in MCL cells.

JuSt-23F reduces ERK 1/2 phosphorylation in MCL cells. It was recently shown that inhibition of BTK effectively abrogates downstream survival pathways activated by BTK, including ERK1/2, in B-cell lymphoma (37). Stimulation by mitogens, such as PMA, eventually leads to phosphorylation of ERK1/2 in T- and B-lymphocytes. Inhibition of MAPK pathways prevented proliferation and transcriptional regulation of genes in B-lymphocytes (37). T-Cell lymphocytes treated with 0.2-20 μM JuSt-23F did not reduce ERK1/2 phosphorylation in PMA-induced cells (Figure 3A). However, JuSt-23F treatment and PMA stimulation resulted in inhibition of ERK 1/2 phosphorylation 1.1- to 1.8-fold in Mino cells and 1.3- to 2.1-fold in Maver-1 cells in a dose-dependent manner (p<0.001; Figure 3B and C). Thus, the BTK-activated ERK1/2 survival pathway is down-regulated in JuSt-23F-treated MCL cells Mino and Maver-1.

Figure 1.
Figure 1.

JuSt-23F-mediated apoptosis after 24 h in cell lines Jurkat, Mino and Maver-1 stained with annexin V/propidium iodide. A: Control, untreated cells (top panel); JuSt-23F-treated 25 μM (bottom panel). The percentage of early apoptotic cells are shown in the bottom square and of late apoptotic cells in the top square. B: Kinetics of apoptosis induction (%) in Jurkat, Mino and Maver-1 cells according to JuSt-23F concentration. Statistical significance was set at p<0.01. Data were prepared from the results of flow cytometric analysis.

Discussion

We described the efficacy of JuSt-23F, a novel small molecule aziridine-based BTK inhibitor, in inhibition of MCL cell proliferation and survival. Our results demonstrated that JuSt-23F has BTK inhibitory activity with IC50 value of 37.2 μM in vitro. Moreover, our novel BTK inhibitor is selectively cytotoxic against B-cells compared to T-cells. Genetic studies of many BCR signaling pathways have highlighted complex redundancies as well as pleiotropic effects on cell types other than B-cells (38, 39). Nevertheless, it was found that BTK was primarily expressed in B-cells, but not in T-cells or plasma cells (40). Thus, BTK represents a uniquely attractive kinase target for selective inhibition of B-cell survival.

Figure 2.
Figure 2.

JuSt-23F-mediated phosphorylation of NF-κB in Jurkat T-cell lymphoma (A) and mantle cell lymphoma Mino (B) and Maver-1 (C) cell lines. Normalized phosphorylation of p65/RelA on serine 536 (pNF-κB) in cells is shown. Cells were untreated; treated with 20 μM JuSt-23F; stimulated with TNFα (5 ng/ml); or treated with TNFα (5 ng/ml) plus 2 μM or 20 μM of JuSt-23F. Statistical significance was set at p<0.05. Data represent the mean±standard deviation of triplicate experiments.

Small-molecule inhibitors of BTK have shown anticancer activities in vitro and in animal models. As a result, BTK inhibitors have become an area of substantial clinical interest. Some years ago LFM-A13 was described as a BTK inhibitor with an IC50 of 17 μM in vitro (41), and has been widely used in preclinical studies as a probe for BTK involvement in various cellular functions. The proteasome inhibitor bortezomib (Velcade, 2006) and lenalidomide (Revlimid, 2013) which target ubiquitin E3 ligase cereblon were approved for the treatment of MCL. Ibrutinib was the third drug approved by the US Food and Drug Administration in 2013 for the treatment of MCL. Ibrutinib was shown to completely and irreversibly inhibit B-cell activation and block signaling pathways downstream of BTK (42-44).

Figure 3.
Figure 3.

JuSt-23F-mediated phosphorylation of ERK1/2 in Jurkat T-cell lymphoma (A) and mantle cell lymphoma Mino (B) and Maver-1 (C) cell lines. Normalized ERK1/2 phosphorylation (pERK) is shown. Cells were untreated; treated with 20 μM JuSt-23F, stimulated with 50 nM phorbol-12-myristate-13-acetate (PMA), or treated with 50 nM PMA plus 0.2, 2 or 20 μM JuSt-23F. Statistical significance was set at p<0.05. Data represent the mean±standard deviation of triplicate experiments.

Our findings revealed that BTK inhibitor JuSt-23F selectively induces apoptosis of MCL cells, but not of Jurkat T-cell lymphoma cells, and targets two pathways of activated BCR, NF-κB and ERK1/2. Many findings support BTK inhibition as a therapeutic approach for the treatment of human diseases, associated with activation of the BCR pathway. Since the NF-κB pathway is essential for B-cell development, proliferation and survival, targeting the NF-κB pathway is an attractive approach for MCL therapy (45). NF-κB is now widely recognized as a key positive regulator of cancer cell proliferation and survival via its ability to transcriptionally activate many pro-survival and anti-apoptotic genes such as XIAP, BCL2, BCL-Xl, IκBA, cIAP1, cIAP2 and survivin (46). Serine phosphorylation at various sites of the p65 subunit of NF-κB has been shown to be important in initiating transcription (47). It was shown that transduction of canonical NF-κB signaling pathway via phosphorylation and degradation of IκBα, IKKs (especially IKκB), also phosphorylates p65/RelA at the serine 536 site within the trans-activating domain. Some research groups have recently demonstrated that p65 phosphorylation on serine 536 stimulated the translocation of p65 into the nucleus via the IKK signaling cascade, independently of effects on IκBα (47, 48).

Recently, phosphorylated serine 536 on p65 was detected in the cytoplasm of four MCL tested cell lines, suggesting that a noncanonical NF-κB pathway may be activated in mantle cell lymphoma. Furthermore, the data suggest that at least some genes transcribed selectively by an NF-κB complex containing a form of p65 phosphorylated on serine 536 were not modulated by proteasome inhibitors (42, 47). We demonstrated that JuSt-23F did not modulate proteasome activity in MCL cells Mino and Maver-1 (data not shown).

Targeting NF-κB in the clinic has thus far been less successful. Activation of BTK triggers a cascade of signaling events that culminates in transcriptional regulation involving NF-κB. The NF-κB survival pathway also has the ability to cross-talk with other survival pathways including PI3K/AKT in various cancer types (50, 51). Therefore, targeting the NF-κB pathway alone may not be sufficient to induce apoptosis of malignant cells and combinations of various inhibitors may be required to achieve the desired effect. Few studies have reported on the role of NF-κB in MCL. Apoptotic processes could be engaged using a pharmacological inhibitor of NF-κB in MCL. Interestingly, Ibrutinib demonstrated a remarkable response rate in patients with relapsed/refractory MCL (43). However, approximately one-third of patients have primary resistance to the drug while other patients appear to lose response and develop secondary resistance. The ERK pathway, which is critical to the pathogenesis, proliferation and survival of MCL cells, is actually the focus of interest for targeted therapy. Recent studies of Ma et al. demonstrated that inhibition of ERK1/2 and AKT phosphorylation correlates well with cellular response to BTK inhibition in cell lines and primary tumors treated with Ibrutinib (44). Bernard et al. also showed BCR-dependent activation in MCL of several important effectors such as SYK, BTK, ERK and STAT3. Moreover, inhibition of the proximal BCR signals results in a complete inhibition of downstream effectors such as ERK or STAT3 and induction of MCL cell apoptosis (52). Reduced migration of MCL Jeko-1 cells, as well as enhanced sensitivity to a chemotherapeutic agent, was associated with decreased phosphorylation of ERK1/2 and AKT kinases (53). Our study suggests JuSt-23F abrogates at least two downstream BTK signaling pathways, ERK1/2 and NF-κB, involved in B-cell lymphoma survival, resulting in induction of MCL cell apoptosis. Thus, our findings coincide with the known data. JuSt-23F might be assessed by combination with the other targeted inhibitors to prevent primary resistance or overcome secondary resistance, as well as improvement of therapy efficacy. We believe that this small-molecule aziridine-based inhibitor is a promising agent for treatment and study of such B-cell malignancy as MCL.

Acknowledgements

This project was supported by European Regional Development Fund, ERAF grant 2DP/2.1.1.1.0/14/APIA/VIAA/064.

Footnotes

  • Conflicts of Interest

    The Authors declare that there are no conflicts of interest.

  • Received July 29, 2016.
  • Revision received September 2, 2016.
  • Accepted September 5, 2016.

References

  1. ↵
    1. Cinar M,
    2. Hamedani F,
    3. Mo Z,
    4. Cinar B,
    5. Amin H,
    6. Alkan S
    : Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by ibrutinib induces apoptosis. Leuk Res 37: 1271-1277, 2013.
    OpenUrlCrossRefPubMed
    1. Smith MR
    : Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene 22: 7359-7368, 2003.
    OpenUrlCrossRefPubMed
    1. Bonavida B
    : Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene 26(25): 3629-3636, 2007.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Pickering BM,
    2. de Mel S,
    3. Lee M,
    4. Howell M,
    5. Habens F,
    6. Dallman CL,
    7. Neville LA,
    8. Potter KN,
    9. Mann J,
    10. Mann DA,
    11. Johnson PW,
    12. Stevenson FK,
    13. Packham G
    : Pharmacological inhibitors of NF-kappaB accelerate apoptosis in chronic lymphocytic leukaemia cells. Oncogene 26: 1166-1177, 2007.
    OpenUrlCrossRefPubMed
  5. ↵
    1. Kim YJ,
    2. Sekiya F,
    3. Poulin B,
    4. Bae YS,
    5. Rhee SG
    : Mechanism of B-cell receptor-induced phosphorylation and activation of phospholipase C-γ2. Mol Cell Biol 24(22): 9986-9999, 2004.
    OpenUrlAbstract/FREE Full Text
  6. ↵
    1. Fluckiger AC,
    2. Li Z,
    3. Kato RM,
    4. Wahl MI,
    5. Ochs HD,
    6. Longnecker R,
    7. Kinet JP,
    8. Witte ON,
    9. Scharenberg AM,
    10. Rawlings DJ
    : Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation. EMBO J 17(7): 1973-1985, 1998.
    OpenUrlAbstract
    1. Jiang A,
    2. Craxton A,
    3. Kurosaki T,
    4. Clark EA
    : Different protein tyrosine kinases are required for B cell antigen receptor-mediated activation of extracellular signal-regulated kinase, c-Jun NH2-terminal kinase 1, and p38 mitogen-activated protein kinase. J Exp Med 188(7): 1297-1306, 1998.
    OpenUrlAbstract/FREE Full Text
    1. Anderson JS,
    2. Teutsch M,
    3. Dong Z,
    4. Wortis HH
    : An essential role for Bruton's tyrosine kinase in the regulation of B-cell apoptosis. Proc Natl Acad Sci USA 93(20): 10966-10971, 1996.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Bajpai UD,
    2. Zhang K,
    3. Teutsch M,
    4. Sen R,
    5. Wortis HH
    : Bruton's tyrosine kinase links the B cell receptor to nuclear factor kappaB activation. J Exp Med 191: 1735-1744, 2000.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Pighi C,
    2. Gu TL,
    3. Dalai I,
    4. Larbi S,
    5. Parolini C,
    6. Bertolaso A,
    7. Pedron S,
    8. Parisi A,
    9. Ren J,
    10. Cecconi D,
    11. Chilosi M,
    12. Menestrina F,
    13. Zamo A
    . Phospho-proteomic analysis of mantle cell lymphoma cells suggests a pro-survival role of B-cell receptor signaling. Cell Oncol 34(2): 141-153, 2011.
    OpenUrlCrossRef
  11. ↵
    1. Pham LV,
    2. Tamayo AT,
    3. Yoshimura LC,
    4. Lo P,
    5. Ford RJ
    : Inhibition of constitutive NF-kappa B activation in mantle cell lymphoma B cells leads to induction of cell cycle arrest and apoptosis. J Immunol 171: 88-95, 2003.
    OpenUrlAbstract/FREE Full Text
    1. Karin M,
    2. Cao Y,
    3. Greten FR,
    4. Li ZW
    : NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2(4): 301-310, 2002.
    OpenUrlCrossRefPubMed
  13. ↵
    1. Karin M
    : Nuclear factor-kappaB in cancer development and progression. Nature 441(7092): 431-436, 2006.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Rudelius M,
    2. Pittaluga S,
    3. Nishizuka S,
    4. Pham TH,
    5. Fend F,
    6. Jaffe ES,
    7. Quintanilla-Martinez L,
    8. Raffeld M
    . Constitutive activation of AKT contributes to the pathogenesis and survival of mantle cell lymphoma. Blood 108(5): 1668-1676, 2006.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Yu L,
    2. Mohamed AJ,
    3. Simonson OE,
    4. Vargas L,
    5. Blomberg KE,
    6. Björkstrand B,
    7. Arteaga HJ,
    8. Nore BF,
    9. Smith CI
    : Proteasome-dependent autoregulation of Bruton tyrosine kinase (BTK) promoter via NF-kappaB. Blood 111(9): 4617-4626, 2008.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    1. Wang SS,
    2. Purdue MP,
    3. Cerhan JR,
    4. Zheng T,
    5. Menashe I,
    6. Armstrong BK,
    7. Lan Q,
    8. Hartge P,
    9. Kricker A,
    10. Zhang Y,
    11. Morton LM,
    12. Vajdic CM,
    13. Holford TR,
    14. Severson RK,
    15. Grulich A,
    16. Leaderer BP,
    17. Davis S,
    18. Cozen W,
    19. Yeager M,
    20. Chanock SJ,
    21. Chatterjee N,
    22. Rothman N
    : Common gene variants in the tumor necrosis factor (TNF) and TNF receptor superfamilies and NF-κB transcription factors and non-Hodgkin lymphoma risk. PLoS One 4(4): e5360, 2009.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Rickert RC,
    2. Jellusova J,
    3. Miletic AV
    : Signaling by the tumor necrosis factor receptor superfamily in B-cell biology and disease. Immunol Rev 244(1): 115-133, 2011.
    OpenUrlCrossRefPubMed
  18. ↵
    1. Dolcet X,
    2. Llobet D,
    3. Pallares J,
    4. Matias-Guiu X
    : NF-κB in development and progression of human cancer Virchows Arch 446(5): 475-482, 2005.
    OpenUrlCrossRefPubMed
  19. ↵
    1. Sakurai H,
    2. Chiba H,
    3. Miyoshi H,
    4. Sugita T,
    5. Toriumi W
    : IkappaB kinases phosphorylate NF-kappaB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 274(43): 30353-30356, 1999.
    OpenUrlAbstract/FREE Full Text
  20. ↵
    1. Sizemore N,
    2. Lerner N,
    3. Dombrowski N,
    4. Sakurai H,
    5. Stark GR
    : Distinct roles of the IκB kinase α and β subunits in liberating nuclear factor κB (NF-κB) from IκB and in phorphorylating the p65 subunit of NF-κB. J Biol Chem 277: 3863-3869, 2002.
    OpenUrlAbstract/FREE Full Text
    1. Buss H,
    2. Dörrie A,
    3. Schmitz ML,
    4. Hoffmann E,
    5. Resch K,
    6. Kracht M
    : Constitutive and interleukin-1-inducible phosphorylation of p65 NF-κB at serine 536 is mediated by multiple protein kinases including IκB kinase (IKK)-α, IKKβ, IKKε, TRAF family member-associated (TANK)-binding kinase 1 (TBK1), and an unknown kinase and couples p65 to TATA-binding protein-associated factor II31-mediated interleukin-8 transcription. J. Biol. Chem 279(53): 55633-55643, 2004.
    OpenUrlAbstract/FREE Full Text
    1. Lawrence T,
    2. Bebien M,
    3. Liu GY,
    4. Nizet V,
    5. Karin M
    : IKKα limits macrophage NF-κB activation and contributes to the resolution of inflammation. Nature 434(7037): 1138-1143, 2005.
    OpenUrlCrossRefPubMed
  23. ↵
    1. Sakurai H,
    2. Suzuki S,
    3. Kawasaki N,
    4. Nakano H,
    5. Okazaki T,
    6. Chino A,
    7. Doi T,
    8. Saiki I
    : Tumor necrosis factor-alpha-induced IKK phosphorylation of NF-kappaB p65 on serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem 278(38): 36916-3623, 2003.
    OpenUrlAbstract/FREE Full Text
  24. ↵
    1. Hofmann WK,
    2. de Vos S,
    3. Tsukasaki K,
    4. Wachsman W,
    5. Pinkus GS,
    6. Said JW,
    7. Koeffler HP
    : Altered apoptosis pathways in mantle cell lymphoma detected by oligonucleotide microarray. Blood 98(3): 787-794, 2001.
    OpenUrlAbstract/FREE Full Text
  25. ↵
    1. Jazirehi AR,
    2. Vega MI,
    3. Chatterjee D,
    4. Goodglick L,
    5. Bonavida B
    : Inhibition of the RAF-MEK1/2-ERK1/2 signaling pathway, BCL-xL down-regulation, and chemosensitization of non-Hodgkin's lymphoma B-cells by Rituximab. Cancer Res 64(19): 7117-1126, 2004.
    OpenUrlAbstract/FREE Full Text
  26. ↵
    1. Dennison JB,
    2. Shanmugam M,
    3. Ayres ML,
    4. Qian J,
    5. Krett NL,
    6. Medeiros LJ,
    7. Neelapu SS,
    8. Rosen ST,
    9. Gandhi V
    : 8-Aminoadenosine inhibits AKT/mTOR and ERK signaling in mantle cell lymphoma. Blood 116(25): 5622-5630, 2010.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    1. Dasmahapatra G,
    2. Lembersky D,
    3. Son MP,
    4. Attkisson E,
    5. Dent P,
    6. Fisher RI,
    7. Friedberg JW,
    8. Grant S
    : Carfilzomib interacts synergistically with histone deacetylase inhibitors in mantle cell lymphoma cells in vitro and in vivo. Mol Cancer Ther 10(9): 1686-1697, 2011.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    1. Robak T,
    2. Robak P
    : BCR signaling in chronic lymphocytic leukemia and related inhibitors currently in clinical studies. Int Rev Immunol 32(4): 358-376, 2013.
    OpenUrlCrossRefPubMed
  29. ↵
    1. Hendriks RW,
    2. Yuvaraj S,
    3. Kil LP
    : Targeting Bruton's tyrosine kinase in B-cell malignancies. Nat Rev Cancer 14(4): 219-232, 2014.
    OpenUrlCrossRefPubMed
  30. ↵
    1. Berridge MV,
    2. Herst PM,
    3. Tan AS
    : Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction. Biotechnol Annu Rev 11: 127-152, 2005.
    OpenUrlCrossRefPubMed
  31. ↵
    1. Romanchikova N,
    2. Trapencieris P,
    3. Zemitis J,
    4. Turks M
    : A novel matrix metalloproteinase-2 inhibitor triazolylmethyl aziridine reduces melanoma cell invasion, angiogenesis and targets ERK1/2 phosphorylation. J Enzyme Inhib Med Chem 29(6): 765-772, 2014.
    OpenUrlPubMed
  32. ↵
    1. Genevier HC,
    2. Hinshelwood S,
    3. Gaspar HB,
    4. Rigley KP,
    5. Brown D,
    6. Saeland S,
    7. Rousset F,
    8. Levinsky RJ,
    9. Callard RE,
    10. Kinnon C,
    11. Lovering RC
    : Expression of Bruton's tyrosine kinase protein within the B-cell lineage. Eur J Immunol 24(12): 3100-3105, 1994.
    OpenUrlCrossRefPubMed
  33. ↵
    1. Cahir-McFarland ED,
    2. Davidson DM,
    3. Schauer SL,
    4. Duong J,
    5. Kieff E
    : NF-kappa B inhibition causes spontaneous apoptosis in Epstein-Barr virus-transformed lymphoblastoid cells. Proc Natl Acad Sci USA 97(11): 6055-6060, 2000.
    OpenUrlAbstract/FREE Full Text
    1. Keller SA,
    2. Schattner EJ,
    3. Cesarman E
    : Inhibition of NF-kappaB induces apoptosis of KSHV-infected primary effusion lymphoma cells. Blood 96(7): 2537-2542, 2000.
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Darnell JE Jr..
    : Transcription factors as targets for cancer therapy. Nat Rev Cancer 2(10): 740-749, 2002.
    OpenUrlCrossRefPubMed
  36. ↵
    1. Hewamana S,
    2. Alghazal S,
    3. Lin TT,
    4. Rowntree C,
    5. Karunanithi K,
    6. Pratt G,
    7. Hills R,
    8. Fegan C,
    9. Brennan P,
    10. Pepper C
    : The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 111(9): 4681-4689, 2008.
    OpenUrlAbstract/FREE Full Text
  37. ↵
    1. Herman SE,
    2. Gordon AL,
    3. Hertlein E,
    4. Ramanunni A,
    5. Zhang X,
    6. Jaglowski S,
    7. Flynn J,
    8. Jones J,
    9. Blum KA,
    10. Buggy JJ,
    11. Hamdy A,
    12. Johnson AJ,
    13. Byrd JC
    : Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 117(23): 6287-6296, 2011.
    OpenUrlAbstract/FREE Full Text
  38. ↵
    1. Texido G,
    2. Su IH,
    3. Mecklenbräuker I,
    4. Saijo K,
    5. Malek SN,
    6. Desiderio S,
    7. Rajewsky K,
    8. Tarakhovsky A
    : The B-cell-specific SRC-family kinase BLK is dispensable for B-cell development and activation. Mol Cell Biol 20(4): 1227-1233, 2000.
    OpenUrlAbstract/FREE Full Text
  39. ↵
    1. Lowell CA
    : Src-family kinases: Rheostats of immune cell signaling. Mol Immunol 41(6-7): 631-643, 2004.
    OpenUrlCrossRefPubMed
  40. ↵
    1. Mohamed AJ,
    2. Yu L,
    3. Bäckesjö CM,
    4. Vargas L,
    5. Faryal R,
    6. Aints A,
    7. Christensson B,
    8. Berglöf A,
    9. Vihinen M,
    10. Nore BF,
    11. Smith CI
    : Bruton's tyrosine kinase (BTK): function, regulation, and transformation with special emphasis on the PH domain. Immunol Rev 228(1): 58-73, 2009.
    OpenUrlCrossRefPubMed
  41. ↵
    1. Mahajan S,
    2. Ghosh S,
    3. Sudbeck EA,
    4. Zheng Y,
    5. Downs S,
    6. Hupke M,
    7. Uckun FM
    : Rational design and synthesis of a novel anti-leukemic agent targeting Bruton's tyrosine kinase (BTK), LFM-A13 [alpha-cyano-beta-hydroxy-beta-methyl-N-(2, 5-dibromophenyl) propenamide]. J Biol Chem 274(14): 9587-9599, 1999.
    OpenUrlAbstract/FREE Full Text
  42. ↵
    1. Honigberg LA,
    2. Smith AM,
    3. Sirisawad M,
    4. Verner E,
    5. Loury D,
    6. Chang B,
    7. Li S,
    8. Pan Z,
    9. Thamm DH,
    10. Miller RA,
    11. Buggy JJ
    : The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci USA 107(29): 13075-13080, 2010.
    OpenUrlAbstract/FREE Full Text
  43. ↵
    1. Wang ML,
    2. Rule S,
    3. Martin P,
    4. Goy A,
    5. Auer R,
    6. Kahl BS,
    7. Jurczak W,
    8. Advani RH,
    9. Romaguera JE,
    10. Williams ME,
    11. Barrientos JC,
    12. Chmielowska E,
    13. Radford J,
    14. Stilgenbauer S,
    15. Dreyling M,
    16. Jedrzejczak WW,
    17. Johnson P,
    18. Spurgeon SE,
    19. Li L,
    20. Zhang L,
    21. Newberry K,
    22. Ou Z,
    23. Cheng N,
    24. Fang B,
    25. McGreivy J,
    26. Clow F,
    27. Buggy JJ,
    28. Chang BY,
    29. Beaupre DM,
    30. Kunkel LA,
    31. Blum KA
    : Targeting BTK with Ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369(6): 507-516, 2013.
    OpenUrlCrossRefPubMed
  44. ↵
    1. Ma J,
    2. Lu P,
    3. Guo A,
    4. Cheng S,
    5. Zong H,
    6. Martin P,
    7. Coleman M,
    8. Wang YL
    : Characterization of ibrutinib-sensitive and -resistant mantle lymphoma cells. Br J Haematol 166(6): 849-861, 2014.
    OpenUrlCrossRefPubMed
  45. ↵
    1. Petro JB,
    2. Rahman SM,
    3. Ballard DW,
    4. Khan WN
    : Bruton's tyrosine kinase is required for activation of IkappaB kinase and nuclear factor kappaB in response to B cell receptor engagement. J Exp Med 191(10): 1745-1754, 2000.
    OpenUrlAbstract/FREE Full Text
  46. ↵
    1. Sethi G,
    2. Ahn KS,
    3. Aggarwal BB
    : Targeting nuclear factor-kappa B activation pathway by thymoquinone: role in suppression of antiapoptotic gene products and enhancement of apoptosis. Mol Cancer Res 6(6): 1059-1070, 2008.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Sasaki CY,
    2. Barberi TJ,
    3. Ghosh P,
    4. Longo DL
    : Phosphorylation of RelA/p65 on Serine 536 defines an I{kappa}B{alpha}-independent NF-{kappa}B pathway. J Biol Chem 280(41): 34538-34547, 2005.
    OpenUrlAbstract/FREE Full Text
  48. ↵
    1. Oh SM,
    2. Lee SH,
    3. Lee BJ,
    4. Pyo CW,
    5. Yoo NK,
    6. Lee SY,
    7. Kim J,
    8. Choi SY
    : A distinct role of neutrophil lactoferrin in RelA/p65 phosphorylation on Ser536 by recruiting TNF receptor-associated factors to IkappaB kinase signaling complex. J Immunol 179(9): 5686-5692, 2005.
    OpenUrl
    1. Camara-Clayette V,
    2. Lecluse Y,
    3. Schrader C,
    4. Klapper W,
    5. Vainchenker W,
    6. Hermine O,
    7. Ribrag V
    :The NF-κB pathway is rarely spontaneously activated in mantle cell lymphoma (MCL) cell lines and patient's samples. Eur J Cancer 50(1): 159-169, 2014.
    OpenUrlPubMed
  50. ↵
    1. Ghosh-Choudhury N,
    2. Mandal CC,
    3. Ghosh Choudhury G
    : Simvastatin induces derepression of PTEN expression via NF-kappaB to inhibit breast cancer cell growth. Cell Signal 22(5): 749-758, 2010.
    OpenUrlCrossRefPubMed
  51. ↵
    1. Han SS,
    2. Yun H,
    3. Son DJ,
    4. Tompkins VS,
    5. Peng L,
    6. Chung ST,
    7. Kim JS,
    8. Park ES,
    9. Janz S
    : NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. Mol Cancer 9: 97-113, 2010.
    OpenUrlCrossRefPubMed
  52. ↵
    1. Bernard S,
    2. Danglade D,
    3. Gardano L,
    4. Laguillier C,
    5. Lazarian G,
    6. Roger C,
    7. Thieblemont C,
    8. Marzec J,
    9. Gribben J,
    10. Cymbalista F,
    11. Varin-Blank N,
    12. Ledoux D,
    13. Baran-Marszak F
    : Inhibitors of BCR signalling interrupt the survival signal mediated by the micro-environment in mantle cell lymphoma. Int J Cancer: 136(12): 2761-2774, 2015.
    OpenUrlCrossRefPubMed
  53. ↵
    1. Kim YR,
    2. Eom KS
    : Simultaneous Inhibition of CXCR4 and VLA-4 Exhibits Combinatorial effect in overcoming stroma-mediated chemotherapy resistance in mantle cell lymphoma cells. Immune Netw 14(6): 296-306, 2014.
    OpenUrlPubMed
View Abstract
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
A Novel Aziridine-based Bruton's Tyrosine Kinase Inhibitor Induces Apoptosis Through Down-regulation of p65/RelA Phosphorylation on Serine 536 and ERK1/2 in Mantle Cell Lymphoma
NADEZHDA ROMANCHIKOVA, ARNIS STRODS, JULIJA STRAZDINA, BORISS STRUMFS, PETERIS TRAPENCIERIS
Anticancer Research Nov 2016, 36 (11) 6133-6140;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Keywords